Tris Pharma’s Onyda XR Gains the US FDA’s Approval for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) 

Shots: 

• The US FDA has granted approval to the company’s QD extended-release oral suspension of Onyda XR (clonidine hydrochloride) with nighttime dosing alone or as adj. to approved central nervous system (CNS) stimulant therapies for ADHD treatment in children (≥6yrs.). Its availability is anticipated in H2’24 

• The approval was supported by the data from studies evaluating clonidine hydrochloride extended-release tablets 

• Onyda XR is the first non-stimulant ADHD medication that has been developed using the comoany’s LiquiXR technology for treating ADHD 

Ref: Tris Pharma | Image: Tris Pharma | Press Release

Related News:- Amgen’s Imdelltra (Tarlatamab-dlle) Receives the US FDA’s Approval to Treat Extensive-Stage Small Cell Lung Cancer 

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com